1. Home
  2. ANNX vs METC Comparison

ANNX vs METC Comparison

Compare ANNX & METC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • METC
  • Stock Information
  • Founded
  • ANNX 2011
  • METC 2015
  • Country
  • ANNX United States
  • METC United States
  • Employees
  • ANNX N/A
  • METC N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • METC Coal Mining
  • Sector
  • ANNX Health Care
  • METC Energy
  • Exchange
  • ANNX Nasdaq
  • METC Nasdaq
  • Market Cap
  • ANNX 668.8M
  • METC 618.9M
  • IPO Year
  • ANNX 2020
  • METC 2017
  • Fundamental
  • Price
  • ANNX $5.14
  • METC $12.56
  • Analyst Decision
  • ANNX Strong Buy
  • METC Strong Buy
  • Analyst Count
  • ANNX 7
  • METC 3
  • Target Price
  • ANNX $15.80
  • METC $19.67
  • AVG Volume (30 Days)
  • ANNX 1.4M
  • METC 556.4K
  • Earning Date
  • ANNX 11-14-2024
  • METC 11-04-2024
  • Dividend Yield
  • ANNX N/A
  • METC 4.39%
  • EPS Growth
  • ANNX N/A
  • METC N/A
  • EPS
  • ANNX N/A
  • METC 0.71
  • Revenue
  • ANNX N/A
  • METC $698,132,000.00
  • Revenue This Year
  • ANNX N/A
  • METC N/A
  • Revenue Next Year
  • ANNX N/A
  • METC $25.55
  • P/E Ratio
  • ANNX N/A
  • METC $17.60
  • Revenue Growth
  • ANNX N/A
  • METC 11.52
  • 52 Week Low
  • ANNX $2.27
  • METC $9.03
  • 52 Week High
  • ANNX $8.40
  • METC $22.70
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 20.42
  • METC 58.79
  • Support Level
  • ANNX $5.05
  • METC $12.08
  • Resistance Level
  • ANNX $7.63
  • METC $13.69
  • Average True Range (ATR)
  • ANNX 0.37
  • METC 0.76
  • MACD
  • ANNX -0.23
  • METC 0.11
  • Stochastic Oscillator
  • ANNX 3.68
  • METC 72.51

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About METC Ramaco Resources Inc.

Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves and resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mill and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. Operations are concentrated in the Appalachian basin, with active mines at Elk Creek, Berwind, Knox Creek, and Maben mining complexes.

Share on Social Networks: